Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment
NCT: NCT07500324 · RECRUITING
Brief Summary
This prospective interventional translational study aims to identify and validate protein biomarkers associated with major ophthalmological diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal detachment (RD). A total of approximately 260 participants (cases and controls) will be enrolled at a single center. Biological samples, including peripheral blood, tears, aqueous humor, vitreous humor, and subretinal fluid, will be collected during routine clinical and surgical procedures. Advanced clinical proteomics approaches will be applied to characterize molecular signatures associated with disease onset, progression, and response to treatment. The study seeks to improve the understanding of disease pathophysiology and support the development of novel diagnostic and prognostic biomarkers in ophthalmology.
Frequently Asked Questions
What is Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment?
Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment is a clinical trial registered under NCT07500324. Current status: RECRUITING.
What is the status of NCT07500324?
The current status of NCT07500324 (Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment) is: RECRUITING.
When did Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment start?
Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment started on 2024-01-24.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.